In patients with HFpEF and obesity, symptom reduction and weight loss provided by semaglutide extends to those with diabetes, suggest new data from the STEP-HFpEF DM trial.
, and diabetes much like it does in similar patients without diabetes, according to results of a pivotal trial likely to expand the drug's approved indications. as an enrollment criterion and showed similar benefits, reported principal investigator Mikhail N. Kosiborod, MD, vice president of research for the St. Luke's Health System, Kansas City, Missouri.
For entry, patients were required to have had at least one HF hospitalization in the previous 12 months and to have abnormal levels of natriuretic peptides at baseline. The majority of patients in both arms of the study were on guideline-directed medical therapy for HFpEF, said Kosiborod, who presented these results in a Featured Clinical Research session at the annual meeting of the American College of Cardiology.
For patients receiving both, an attenuation of relative benefit from semaglutide was observed for KCCQ-CSS and weight loss . Yet, the direction of benefit was the same and remained significant for weight loss regardless of SGLT2 exposure, Kosiborod reported.events was low in both arms and not significantly different, but there was a significantly lower rate of cardiac disorders and a numerically lower rate of all-cause mortality for those randomized to semaglutide.
"There is evidence to suggest that the mechanics of heart failure is different in patients with diabetes relative to those with obesity," she said. Now with data from STEP-HFpEF DM, there is evidence that the same type of benefit is achieved "when the two metabolic diseases occur together."
Obesity Obese Weight Loss Diabetes Mellitus Type 2 Diabetes Mellitus Type Ii Type 2 Diabetes Type 2 DM T2DM T2D Weight Management Quality Of Life QOL Health Related Quality Of Life Health-Related Quality Of Life HRQOL Cardiovascular Imaging Cardiac Imaging CV Imaging CV Risk Cardiovascular Risk CV Risk Factors Cardiovascular Risk Factors
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Thousands of BCBSAZ patients out of network at Dignity Health, Aetna patients also at riskThousands are now out of network at Dignity, others at risk of losing coverage
Read more »
A faster, cheaper way to synthesize diabetes and weight loss drugs like semaglutideSemaglutide is part of the glucagon-like peptide-1 (GLP-1) receptor targeting family of peptide drugs which are mainly used to treat diabetes but are difficult and expensive to make.
Read more »
Vanishing Fat: Semaglutide’s Triumph Over HIV Liver DiseaseScience, Space and Technology News 2024
Read more »
Review Describes Skin Effects Associated With SemaglutideAlopecia, dysesthesia, and other types of skin sensations have been reported in patients treated with semaglutide, but more research is needed to understand skin findings associated with this drug.
Read more »
Study Finds High TIL Levels Associated with Better Prognosis for Breast Cancer PatientsA recent study published in the Journal of the American Medical Association has found that breast cancer patients with high levels of tumor-infiltrating lymphocytes (TILs) have a better prognosis. The study aimed to explore whether patients with a favorable prognosis can avoid intensive chemotherapy regimens. Researchers followed patients for an average of 18 years and found that five years after surgery, 95% of patients with high TIL levels were still alive, compared to 82% of patients with low TIL levels. The recurrence rate for breast cancer was also significantly lower among those with high TIL levels.
Read more »
Delaying Inguinal Hernia Repair Beneficial for Preterm InfantsA new study suggests that delaying inguinal hernia repair in preterm infants until after NICU discharge results in better outcomes compared with performing repair procedures before discharge.
Read more »